首页> 外文期刊>Pediatric blood & cancer >Multifactorial analysis of opsoclonus‐myoclonus syndrome etiology (“Tumor” vs. “No tumor”) in a cohort of 356 US children
【24h】

Multifactorial analysis of opsoclonus‐myoclonus syndrome etiology (“Tumor” vs. “No tumor”) in a cohort of 356 US children

机译:多硒 - 肌肉综合征病因的多因素分析(“肿瘤”与“肿瘤”与“No Tumor”)中的356个美国儿童队列

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background Pediatric opsoclonus‐myoclonus syndrome (OMS) presents a paradox of etiopathogenesis: A neuroblastic tumor (NB) is found in only one half of the cases, the others are ascribed to infections or designated as idiopathic. Method From an IRB‐approved observational study of 356 US children with OMS, secondary analysis of “etiology” and related factors was performed on a well‐characterized cohort. The “Tumor” (n?=?173) and “No Tumor” groups (n?=?183), as defined radiologically, were compared according to multiple factors considered potentially differentiating. Data were analyzed retrospectively using parametric and nonparametric tests as indicated. Results Patients with NB were not distinguishable by prodromal symptoms, OMS onset age, gender, race/ethnicity, OMS severity, rank order of neurological sign appearance, or geographic distribution. Various CSF immunologic biomarker abnormalities of OMS did not vary in the presence or absence of a detectable tumor: frequency of six lymphocyte subsets, or concentrations of 18 cytokines/chemokines, cytokine antagonists, chemokine receptors, cell adhesion molecules, or neuronal/glial markers. Prior responsiveness to conventional immunotherapy was not contingent on tumor/no tumor designation. Conclusions Multiple convergent factors provide compelling empirical evidence and rationalize the concept that OMS is one neurological disorder, regardless of apparent etiology. Limitations to the current clinical etiologic classifications as paraneoplastic, parainfectious/post‐infectious, and idiopathic etiology require antigen‐based biological solutions to tease out the molecular pathophysiology of viral/tumoral mechanisms. Systematic studies, regardless of presumed etiology, will be necessary to find the highest‐yield combination of imaging approaches, screening for infectious agents, and new biomarkers. Two testable hypotheses for future research are presented.
机译:摘要背景儿科蛋白酶蛋白综合征(OMS)呈现了病原生成的悖论:只有一半的病例中发现神经细胞肿瘤(NB),其他患者归因于感染或被指定为特性。来自IRB批准的IMS批准的观察研究的方法,对肿瘤的二次分析和相关因子进行了二次分析和相关因素。根据认为可能分化的多种因素比较“肿瘤”(n?=α173)和“无肿瘤”基团(n?=β183),比较。按照所示,回顾性地分析数据和非参数测试。结果Nb患者不能通过前驱症状,OMS发作年龄,性别,种族/种族,OMS严重程度,神经迹象表观等级排序,或地理分布。各种CSF免疫生物标志物OMS的异常在可检测肿瘤的存在或不存在下没有变化:六个淋巴细胞亚群的频率,或18个细胞因子/趋化因子,细胞因子拮抗剂,趋化因子,细胞粘附分子或神经元/胶质标记的浓度。对常规免疫疗法的敏感性不存在于肿瘤/无肿瘤指定上。结论多种收敛因素提供了令人信服的经验证据,并合理化OMS是一种神经疾病的概念,无论表观的病因如何。当前临床病因分类的限制为偏静脉,垂直/后传染病和特发科病因需要抗原的生物解决方案,以梳除病毒/肿瘤机制的分子病理学生理学。无论推定的病因如何,系统研究将是必要的,以找到成像方法的最高产量组合,筛查传染病,以及新的生物标志物。提出了两个可测试的假设,用于将来研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号